Open Label, Randomized, Cross-over Study to Explore the Pharmacokinetics of BAY1834845 After Oral and Intravenous Dosing, Including Food Effect and Absolute Bioavailability (Part A), and to Investigate the Effect of BAY1834845 on the Pharmacokinetics of Orally Administered Methotrexate (Part B) in Healthy Male Subjects
Phase of Trial: Phase I
Latest Information Update: 17 Nov 2017
At a glance
- Drugs BAY 1834845 (Primary) ; BAY 1834845 (Primary) ; Methotrexate
- Indications Pelvic inflammatory disorders
- Focus Pharmacokinetics
- Sponsors Bayer
- 10 Nov 2017 Planned End Date changed from 31 Jan 2018 to 28 Feb 2018.
- 10 Sep 2017 Status changed from not yet recruiting to recruiting.
- 14 Aug 2017 New trial record